Metastatic Urothelial Carcinoma

The FDA granted priority review to enfortumab vedotin for treatment of certain patients with locally advanced or metastatic urothelial cancer.

The addition of atezolizumab to platinum-based chemotherapy extended PFS among patients with previously untreated advanced bladder cancer, according to results released by the agent’s manufacturer.